|
Dr. Loberg joined Kereos as a board member in January 2004. He recently served as President and CEO of NitroMed, and also on the board of Advanced Magnetics. In 2003 Dr. Loberg oversaw and led NitroMed’s initial public offering process. Previously, Dr. Loberg spent nearly 20 years with the Bristol-Myers Squibb (BMS) organization, most recently as President, BMS Oncology & Immunology. He also served as President, BMS Primary Care division; President, BMS Northern Europe; President, BMS Specialty Pharmaceuticals; President, Squibb Diagnostics; and Vice President for Diagnostic R&D, E.R. Squibb & Sons. Prior to BMS, Dr. Loberg served as Associate Professor in the University of Maryland Schools of Pharmacy and Medicine. He holds a Ph.D. in Chemistry from Washington University. | 